Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma

Oncoscience

Volumn 2, Issue 2, 2015, Pages 151-186

  Sanders, Edward ^a   Diehl, Svenja ^b  

^a Edward Sanders Scientific Consulting   (Switzerland)

^b Freelancer Bioinformatics   (Germany)

Author keywords

Aerobic glycolysis; Clear cell renal cell carcinoma; Transcriptomics; Warburg effect

Indexed keywords

EID: 84938224252     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.128     Document Type: Article

References (230)

1. Warburg O. On the origin of cancer cells. Science. 1956(3191);123:309-314.
2. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891-899.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
4. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics. 2004;84(6):1014-1020.
5. Ding L, Getz G, Wheeler DA, Mardis, ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069-1075.
6. Nam SO, Yotsumoto F, Miyata K, Shirasu N, Miyamoto S, Kuroki M. Possible therapeutic targets among the molecules involved in the Warburg effect in tumor cells. Anticancer Res. 2013;33(7):2855-2860.
7. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell. 2013;155(2):397-409.
8. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res. 2007;13(16):4740-4749.
9. Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ, Copland JA. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One. 2010;5(5):e10696.
10. Schmoll D, Balabanov S, Schwarck D, Burchell A, Kleist B, Zimmermann U, Walther R. Differential expression of the subunits of the glucose-6-phosphatase system in the clear cell type of human renal cell carcinoma-no evidence for an overexpression of protein kinase B. Cancer Lett. 2001;167(1):85-90.
11. Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, Harris AL. Expression of hypoxiainducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res. 2002;62(10):2957-2961.
12. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer. 2005;5(11):857-866.
13. Sanders E. Pseudohypoxia, mitochondrial mutations, the Warburg effect and cancer. Biomed Res. 2012;23(SI):109-131.
14. Dayan F, Roux D, Brahimi-Horn MC, Pouyssegur J, Mazure NM. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor 1a. Cancer Res. 2006;66(7):3688-3698.
15. Stubbs M, Griffiths JR. The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Adv Enzyme Regul. 2010;50(1):44-55.
16. Semenza GL. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J. Bioenerg Biomembr. 2007;39(3):231-234.
17. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer.2008;8(9):705-713.
18. McFate T, Mohyeldin A, Lu H, Thakar J, Henriques J, Halim ND, Wu H, Schell MJ, Tsang TM, Teahan O, Zhou S, Califano JA, Jeoung NH, et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem. 2008;283(33):22700-22708.
19. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem. 2009;9(9):1084-1101.
20. Kim JJ, Rini BI, Hansel DE. Von Hippel LIndau syndrome. Adv Exp Med Biol. 2010;685:228-249.
21. Ozcan A, Shen SS, Zhai QJ, Truong LD. Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. Am J Clin Pathol. 2007;128(2):245-254.
22. Mathupala SP, Ko YH, Pedersen PL. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta. 2010;1797(6-7):1225-1230.
23. Pedersen PL. Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg effect", i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr. 2007;39(3):211-222.
24. Gelb BD, Adams V, Jones SN, Griffin LD, MacGregor GR, McCabe ER. Targeting of hexokinase 1 to liver and hepatoma mitochondria. Proc Natl Acad Sci USA. 1992;89(1):202-206.
25. Pastorino JG, Hoek JB. Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr. 2008;40(3):171-182.
26. Moeller LC, Dumitrescu AM, Refetoff S. Cytosolic action of thyroid hormone leads to induction of hypoxiainducible factor-1a and glycolytic genes. Mol Endocrinol. 2005;19(12):2955-2963.
27. Liang GP, Su YY, Chen J, Yang ZC, Liu YS, Luo XD. Analysis of the early adaptive response of endothelial cells to hypoxia via a long serial analysis of gene expression. Biochem Biophys Res Commun. 2009;384(4):415-419.
28. Chen L, Qiu JH, Zhang LL, Luo XD. Adrenomedullin promotes human endothelial cell proliferation via HIF-1a. Mol Cell Biochem. 2012;365(1-2):263-273.
29. Sanchez-Martinez C, Estevez AM, Aragon JJ. Phosphofructokinase C isozyme from ascites tumor cells: cloning, expression, and properties. Biochem Biophys Res Commun. 2000;271(3):635-640.
30. Moon JS, Kim HE, Koh E, Park SH, Jin WJ, Park BW, Park SW, Kim KS. Krüppel-like factor 4 (KLF4) activates the transcription of the gene for the platelet isoform of phosphofructokinase (PFKP) in breast cancer. J Biol Chem. 2011;286(27):23808-23816.
31. Song E, Ma X, Li H, Zhang P, Ni D, Chen W, Gao Y, Fan Y, Pang H, Shi T, Ding Q, Wang B, Zhang Y, Zhang X. Attenuation of Krüppel-like factor 4 facilitates carcinogenesis by inducing G1/S phase arrest in clear cell renal cell carcinoma. PLoS One. 2013;8(7):e67758.
32. Rider MH, Bertrand L, Vertommen D, Michels PA, Rousseau GG, Hue L. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. Biochem J. 2004;381(Pt 3):561-579.
33. Van Schaftingen E, Hers HG. Phosphofructokinase 2: the enzyme that forms fructose 2,6-bisphosphate from fructose 6-phosphate and ATP. Biochem Biophys Res Comm. 1981;101(3):1078-1084.
34. Bando H, Atsumi T, Nishio T, Niwa H, Mishima S, Shimizu C, Yoshioka N, Bucala R, Koike T. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphophatase/PFKFB3 family of glycolytic regulators in human cancer. Clin Cancer Res. 2005;11(16):5784-5792.
35. Kessler R, Eschrich K. Splice isoforms of ubiquitous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in human brain. Brain Res Mol Brain Res. 2001;87(2):190-195.
36. Choi IY, Wu C, Okar DA, Lange AJ, Gruetter R. Elucidation of the role of fructose 2,6-bisphosphate in the regulation of glucose fluxes in mice using in vivo 13C NMR measurements of hepatic carbohydrate metabolism. Eur J Biochem. 2002;269(18):4418-4426.
37. Jin ES, Uyeda K, Kawaguchi T, Burgess SC, Malloy CR, Sherry AD. Increased hepatic fructose 2,6-bisphosphate after an oral glucose load does not affect gluconeogenesis. J Biol Chem. 2003;278(31):28427-28433.
38. Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol. 2009;86(3):174-179.
39. Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell R, Bucala R. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res. 2002;62(20):5881-5887.
40. Minchenko OH, Ochiai A, Opentanova IL, Ogura T, Minchenko DO, Caro J, Komisarenko SV, Esumi H. Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. Biochemie. 2005;87(11):1005-1010.
41. Minchenko OH, Ogura T, Opentanova IL, Minchenko DO, Ochiai A, Caro J, Komisarenko SV, Esumi H. 6-Phophofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor. Ukr Biokhim Zh. 2005;77(6):46-50.
42. Bobarykina AY, Minchenko DO, Opentanova IL, Moenner M, Caro J, Esumi H, Minchenko OH. Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers. Acta Biochim Pol. 2006;53(4):789-799.
43. Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, Caro J. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem.2002;277(8):6183-6187.
44. Minchenko O, Opentanova I, Caro J. Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB1-4) expression in vivo. FEBS Lett. 2003;554(3):264-270.
45. Obach M, Navarro-Sabaté A, Caro J, Kong X, Duran J, Gomez M, Perales JC, Ventura F, Rosa JL, Bartrons R. 6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sties necessary for transactivation in response to hypoxia. J Biol Chem. 2004;279(51):53562-53570.
46. Minchenko O, Opentanova I, Minchenko D, Ogura T, Esumi H. Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 gene via hypoxiainducible factor-1a activation. FEBS Lett. 2004;576(1-2):14-20.
47. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-indcible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107-120.
48. Ando M, Uehara I, Kogure K, Asano Y, Nakajima W, Abe Y, Kawauchi K, Tanaka N. Interleuken 6 enhances glycolysis through expression of the glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3. J Nippon Med Sch. 2010;77(2):97-105.
49. Novellasdemunt L, Obach M, Millan-Arino L, Manzano A, Ventura F, Rosa JL, Jordan A, Navarro-Sabate A, Bartrons R. Progestins activate 6-phosphofructo-2-kinase/fructose-2,6-phosphatase 3 (PFKFB3) in breast cancer cells. Biochem J. 2012;442(2):345-356.
50. Calvo MN, Bartrons R, Castano E, Perales JC, Navarro-Sabaté A, Manzano A. PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells. FEBS Lett. 2006;580(13):3308-3314.
51. Hirata T, Watanabe M, Miura S, Ijichi K, Fukasawa M, Sakakibara N. Inhibition of tumor cell growth by a specific 6-phosphofructo-2-kinase inhibitor, N-bromoacetylethanolamine phosphate, and its analogues. Biosci Biotechnol Biochem. 2000;64(10):2047-2052.
52. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eton J, Lane A, Trent JO, Chesney J. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008;7(1):110-120.
53. Seo M, Kim JD, Neau D, Sehgal I, Lee YH. Structurebased development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect. PLoS One. 2011;6(9):e24179.
54. Sakakibara R, Kato M, Okamura N, Nakagawa T, Komada Y, Tominaga N, Shimojo M, Fukasawa M. Characterization of a human placental fructose-6-phosphate, 2-kinase/fructose-2,6-bisphosphatase. J. Biochem. 1997, 122(1):122-128.
55. Sakakibara R, Uemura M, Hirata T, Okamura N, Kato M: Human placental fructose-6-phosphate, 2-kinase/fructose-2,6-bisphosphatase: its isozymic form, expression and characterization. Biosci Biotechnol Biochem 1997;61(11):1949-1952.
56. Okar DA, Manzano A, Navarro-Sabatè A, Riera L, Bartrons R, Lange AJ. PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2.6-bisphosphate. Trends Biochem Sci. 2001;26(1):30-35.
57. Hue L, Beauloye C, Bertrand L, Horman S, Krause U, Marsin AS, Meisse D, Vertommen D, Rider MH: New targets of AMP-activated protein kinase. Biochem Soc Trans. 2003;31(Pt 1):213-215.
58. Ros S, Santos CR, Moco S., Baenke F, Kelly G, Howell M, Zamboni N, Schulze A. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov. 2012;2(4):328-343.
59. Goidts V, Bageritz J, Puccio L Nakata S, Zapatka M, Barbus S, Toedt G, Campos B, Korshunov A, Momma S, Van Schaftingen E, Reifenberger G, Herold-Mende C, et al. RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene. 2012;31(27):3235-3243.
60. Mendelsohn AR, Larrick JW. Paradoxical effects of antioxidants on cancer. Rejuvenation Res. 2014;17(3):306-311.
61. Yalcin A, Clem BF, Simmons A, Lane A, Nelson K, Clem AL, Brock E, Siow D, Wattenberg B, Telang S, Chesney J. Nuclear targeting of 6-phosphofructo-2-kinsae (PFKFB3) increases proliferation via cyclin-dependent kinases. J Biol Chem. 2009;284(36):24223-24232.
62. Dang, CV. Cancer cell metabolism: there is no ROS for the weary. Cancer Discov. 2012;2(4):304-307.
63. Zhu YY, Takashi M, Miyake K, Kato K. An immunochemical and immunohistochemical study of aldolase isozymes in renal cell carcinoma. J Urol. 1991;146(2):469-472.
64. Takashi M, Zhu Y, Nakano Y, Miyake K, Kato K. Elevated levels of serum aldolase A in patients with renal cell carcinoma. Urol Res. 1992;20(4):307-311.
65. Castaldo G, Calcagno G, Sibillo R, Cuomo R, Nardone G, Castellano L, Del Vecchio Blanco C, Budillon G, Salvatore F. Quantitative analysis of aldolase A mRNA in liver discriminates between hepatocellular carcinoma and cirrhosis. Clin Chem. 2000;46(7):901-906.
66. Unwin, RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ, Banks RE. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics. 2003;3(8):1620-1632.
67. Said HM, Hagemann C, Stojic J, Schoemig B, Vince GH, Flentje M, Roosen K, Vordermark D. GADPH is not regulated in human glioblastoma under hypoxic conditions. BMC Mol Biol. 2007;8:55.
68. Said HM, Polat B, Hagemann C, Anacker J, Flentje M, Vordermark D. Absence of GADPH regulation in tumor cells of different origin under hypoxic conditions in-vitro. BMC Res Notes. 2009;2:8.
69. Kashyap MK, Kumar A, Emelianenko N, Kashyap A, Kaushik R, Huang R, Khullar M, Sharma SK, Singh SK, Bhargave AK, Upadhyaya SK. Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers. 2005;10(4):258-294.
70. Takashi M, Haimoto H, Tanaka J, Murase T, Kato K. Evaluation of gamma-enolase as a tumor marker for renal cell carcinoma. J Urol. 1989;141(4):830-834.
71. Takashi M, Sakata T, Kato K. Use of serum gamma-enolase and aldolase A in combination as markers for renal cell carcinoma. Jpn J Cancer Res. 1993;84(3):304-309.
72. Yaman O, Baltaci S, Arikan N, Ozdiler E, Gogus O, Muftuoglu YZ. Serum neuron specific enolase: can it be a tumour marker for renal cell carcinoma? Int Urol Nephrol. 1996;28(2): 207-210.
73. Rasmuson T, Grankvist K, Roos G, Ljungberg B. Neuroendocrine differentiation in renal cell carcinoma-evaluation of chromgranin A and neuron-specific enolase. Acta Oncol. 1999;38(5):623-628.
74. Teng PN, Hood BL, Sun M, Dhir R, Conrads TP. Differential proteomic analysis of renal cell carcinoma tissue interstitial fluid. J Proteome Res. 2011;10(3):1333-1342.
75. Westlin J, Edgren M, Letocha H, Stridsberg M, Wilander E, Nilsson S. Positron emission tomography utilizing C-11 5-hydroxytrytophan, plasma biochemistry and neuroendocrine immunohistochemistry of metastatic renalcell carcinoma. Oncol Rep. 1995;2(4):543-548.
76. Ronkainen H, Soini Y, Vaarala MH, Kauppila S, Hirvikoski P. Evaluation of neuroendocrine markers in renal cell carcinoma. Diagn Pathol. 2010;5:28.
77. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, Kültz D, Weiss RH. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer. 2006;5:64.
78. Sun CY, Zang YC, San YX, Sun W, Zhang L. Proteomic analysis of clear cell renal cell carcinoma. Identification of potential tumor markers. Saudi Med J. 2010;31(5):525-532.
79. La Rosa S, Bernasconi B, Micello D, Finzi G, Capella C. Primary small cell neuroendocrine carcinoma of the kidney: morphological, immunohistochemical, ultrastructural, and cytogenetic study of a case and review of the literature. Endocr Pathol. 2009;20(1):24-34.
80. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, Cantley LC. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science. 2010;329(5998):1492-1499.
81. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, Chen WW, Barrett FG, Stransky N, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476(7360):346-350.
82. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarkey E, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011;43(9):869-874.
83. Vazquez A, Markert EK, Oltvai ZN. Serine biosynthesis with one carbon catabolism and the glycine cleavage system represents a novel pathway for ATP generation. PLoS One. 2011;6(11):e25881.
84. Vié N, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B, Frasion C, Conseiller E, Molina F, Larroque C, Martineau P, Del Rio M, Gongora C. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer. 2008;7:14.
85. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2011;43(7):969-980.
86. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res. 1997;17(4B):3153-3156.
87. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15(4):300-308.
88. Jurica MS, Mesecar A, Heath PJ, Shi W, Nowak T, Stoddard BL. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure. 1998;6(2):195-210.
89. Mazurek S, Eigenbrodt E. The tumor metabolome. Anticancer Res. 2003;23(2A):1149-1154.
90. Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry. 2005;44(27):9417-9429.
91. Kumar S, Barth. The allosteric effect of fructose bisphosphate on muscle pyruvate kinase studied by infrared spectroscopy. J Phys Chem B. 2011;115(39):11501-11505.
92. Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012;8(10):839-847.
93. Morgan HP, O'Reilly FJ, Wear MA, O'Neill JR, Fothergill-Gillmore LA, Hupp T, Walkinshaw MD: M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation. Proc Natl Acad Sci USA. 2013;110(15):5881-5886.
94. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog. 1992;3(1-2):91-115.
95. Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A, Coyle JE, Jankevics A, Holding FP, Vousden KH, Frezza C, O'Reilly M, Gottlieb E. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. 2012;491(7424):458-462.
96. Presek P, Reinacher M, Eigenbrodt E. Pyurvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus. FEBS Lett. 1988;242(1):194-198.
97. Mazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc. 2007;(4):99-124.
98. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, et al.: Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009;2(97):ra73.
99. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosinebinding protein. Nature. 2008;452(7184):181-186.
100. Parnell KM, Foulks JM, Nix RN, Clifford A, Bullough J, Luo B, Senina A, Vollmer D, Liu J, McCarthy V, Xu Y, Saunders M, Liu XH, et al. Pharmacological activation of PKM2 slows lung tumor xenograft growth. Mol Cancer Ther. 2013;12(8):1453-1460.
101. Lüftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res. 2000;20(6D):5077-5082.
102. Yilmaz S, Ozan S, Ozercan IH. Comparison of pyruvate kinase variants from breast tumor and normal breast. Arch Med Res. 2003;34(4):315-324.
103. Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G, Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res. 2002;22(1A):311-318.
104. Schneider J, Peltri G, Bitterlich N, Philipp M, Velcovsky HG, Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. Clin Exp Med. 2003;2(4):185-191.
105. Kaura B, Bagga R, Patel F. Evaluation of the pyruvate kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res. 2004;30(3):193-196.
106. Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer. 2005;117(5):825-830.
107. Tonus C, Sellinger M, Koss K, Neupert G. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol. 2012;18(30):4004-4011.
108. Yamada K, Noguchi T. Nutrient and hormonal regulation of pyruvate kinase gene expression. Biochem J. 1999;337(Pt 1):1-11.
109. Brinck U, Eigenbrodt E, Oehmke M, Mazurek S, Fischer G. L-and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch. 1994;424(2):177-185.
110. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010;463(7279):364-368.
111. Chen M, David CJ, Manley JL. Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins. Nat Struct Mol Biol. 2012;19(3):346-354.
112. Bluemlein K, Grüning NM, Feichtinger RG, Lehrach H, Kofler B, Ralser M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget. 2011;2(5):393-400.
113. Wechsel HW, Petri E, Bichler KH, Feil. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res. 1999;19(4A):2583-2590.
114. Oremek GM, Sapoutzis N, Kramer W, Bickeböller R, Jonas D. Value of tumor-M2 (Tu M2-PK) in patients with renal carcinoma. Anticancer Res. 2000;20(6D):5095-5098.
115. Hegele A, Varga Z, Kosche B, Stief T, Heidenreich A, Hofmann R. Pyruvate kinase type tumor M2 in urological malignancies. Urol Int. 2003;70(1):55-58.
116. Johann DJ Jr, Wei BR, Prieto DA, Chan KC, Ye X, Valera VA, Simpson RM, Rudnick PA, Xiao Z, Issaq HJ, Linehan WM, Stein SE, Veenstra TD, Blonder J. Combined blood/tissue analysis for cancer biomarker discovery: application to renal cell carcinoma. Anal Chem. 2010;82(5):1584-1588.
117. Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, Pode D. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology. 2010;76(2):513.e1-6.
118. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297-308.
119. Triplitt CL. Understanding the kidneys' role in blood glucose regulation. Am J Manag Care. 2012;18(1 Suppl):S11-S16.
120. Jitrapakdee S, Vidal-Puig A, Wallace J. Anaplerotic roles of pyruvate carboxylase in mammalian tissues. Cell Mol Life Sci. 2006;63(7-8):843-854.
121. Nordlie RC, Lardy HA. Mammalian liver phosphenolpyruvate carboxykinase activities. J Biol Chem. 1963;238:2259-2263.
122. Watford M, Hod Y, Chiao YB, Utter MF, Hanson RW. The unique role of the kidney in gluconeogenesis in the chicken. The significance of a cytosolic form of phosphoenolpyruvate carboxykinase. J Biol Chem. 1981;256(19):10023-10027.
123. Burgess SC, He T, Yan Z, Lindner J, Sherry AD, Malloy CR, Browning JD, Magnuson MA. Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab. 2007;5(4):313-320.
124. Chakravarty K, Cassuto H, Reshef L, Hanson RW. Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C. Crit Rev Biochem Mol Biol. 2005;40(3):129-154.
125. Lardy HA, Paetkau V, Walter P. Paths of carbon in gluconeogenesis and lipogenesis: the role of mitochondria in supplying precursors of phosphoenolpyruvate. Proc Natl Acad Sci USA. 1965;53(6):1410-1415.
126. Rognstad R, Katz J. Gluconeogenesis in the kidney cortex. Effects of D-malate and amino-oxyacetate. Biochem J. 1970;116(3):483-491.
127. Rajas F, Jourdan-Pineau H, Stefanutti A, Mrad EA, Iynedjian PB, Mithieux. Immunocytochemical localization of glucose 6-phosphatase and cytosolic phosphoenolpyruvate carboxykinase in gluconeogenic tissues reveals unsuspected metabolic zonation. Histochem Cell Biol. 2007;127(5):555-565.
128. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, Teh BT. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA. 2001;98(17):9754-9759.
129. Takahashi M, Teh BT, Kanayama HO. Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling. J Med Invest. 2006;53(1-2):9-19.
130. Penhoet EE, Kochman M, Rutter WJ. Isolation of fructose diphosphate aldolases A, B, and C. Biochemistry. 1969;8(11):4391-4395.
131. Eagles PA, Iqbal M. A comparative study of aldolase from human muscle and liver. Biochem J. 1973;133(3):429-439.
132. Yanez AJ, Ludwig HC, Bertinat R, Spichiger C, Gatica R, Berlien G, Leon O, Brito M, Concha II, Slebe JC. Different involvement for aldolase isoenzymes in kidney glucose metabolism: aldolase B but not aldolase A colocalizes and forms a complex with FBPase. J Cell Physiol. 2005;202(3):743-753.
133. Bouteldja N, Timson DJ. The biochemical basis of hereditary fructose intolerance. J Inherit Metab Dis. 2010;33(2):105-112.
134. Ali M, Rellos P, Cox TM. Hereditary fructose intolerance. J Med Genet. 1998;35(5):353-365.
135. Coffee EM, Yerkes L, Ewen EP, Zee T, Tolan DR. Increased prevalence of mutant null alleles that cause hereditary fructose intolerance in the American population. J Inherit Metab Dis. 2010;33(1):33-42.
136. Hwa JS, Kim HJ, Goo BM, Park HJ, Kim CW, Chung KH, Park HC, Chang SH, Kim YW, Kim DR, Cho GJ, Choi WS Kang KR. The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma. Proteomics. 2006;6(3):1077-1084.
137. Peng JP, Zhang J, Hwang HW, Wang FH, Du XJ, Luo PC. L-arginine-glycine amidinotransferase, betainehomocysteine S-methlytransferase, and neuropolypeptide H3 are diminished in renal clear cell carcinoma of humans. Saudi Med J. 2011.32(5):467-473.
138. Aparicio LM, Villaamil V, Calvo MB, Rubira LV, Rois JM, Valladares-Ayerbes M, Campelo RG, Bolos MV, Pulido EG. Glucose transporter expression and the potential role of fructose in renal cell carcinoma: a correlation with pathological parameters. Mol Med Rep. 2010;3(4):575-580.
139. Medina Villaamil V, Aparicio Gallego G, Valbuena Rubira L, Garcia Campelo R, Valladares-Ayerbes M, Grande Pulido E, Victoria Bolos M, Santamarina Cainzos I, Anton Aparicio LM. Fructose transporter GLUT5 expression in clear renal cell carcinoma. Oncol Rep. 2011;25(2):315-323.
140. Steinberg P, Störkel S, Oesch F, Thoenes W. Carbohydrate metabolism in human renal clear cell carcinomas. Lab Invest. 1992;67(4):506-511.
141. Li B, Qiu B, Lee DS, Walton ZE, Ochocki JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I, Simon MC. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature. 2014;513(7517):251-255.
142. Snell, K. Enzymes of serine metabolism in normal and neoplastic rat tissues. Biochim Biophys Acta. 1985;843(2):276-281.
143. Toyama A, Suzuki A, Shimada T, Aoki C, Aoki Y, Umino Y, Nakamura Y, Aoki D, Sato TA. Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers. Cancer Sci. 2012;103(4):747-755.
144. Souchelnytskyi S, Lomnytska M, Dubrovska A, Hellman U, Volodko N. Proteomics success story. Towards early detection of breast and ovarian cancer: plasma proteomics as a tool to find novel markers. Proteomics. 2006;6(Suppl 2):65-68.
145. Bluemlein K, Glückmann M, Grüning NM, Feichtinger R, Krüger A, Wamelink M, Lehrach H, Tate S, Neureiter D, Kofler B, Ralser M. Pyruvate kinase is a dosage-dependent regulator of cellular amino acid homeostasis. Oncotarget. 2012;3(11):1356-1369.
146. Ferreira LM, Hebrant A, Dumont JE. Metabolic reprogramming of the tumor. Oncogene. 2012;31(36):3999-4011.
147. Icard P, Lincet H: A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim Biophys Acta. 2012;1826(2):423-433.
148. Boros LG, Puigjaner J, Cascante M, Lee WN, Brandes JL, Bassilian S, Yusuf FI, Williams RD, Muscarella P, Melvin WS, Schirmer WJ. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res. 1997;57(19):4242-4248.
149. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan, N, Popa J, Ternullo MP, Steidler A, Weiss C, Grobholz R, Willeke F, Alken P, et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer. 2006;94(4):578-585.
150. Zhao F, Mancuso A, Bui TV, Tong X, Gruber JJ, Swider CR, Sanchez PV, Lum JJ, Sayed N, Melo JV, Perl AE, Carroll M, Tuttle SW, Thompson CB. Imatinib-resistance associated with BCR-ABL upregulation is dependent on HIF-1a-induced metabolic reprograming. Oncogene. 2010;29(20):2962-2972.
151. Krockenberger M, Engel JB, Schmidt M, Kohrenhagen N, Häusler SF, Dombrowski Y, Kapp M, Dietl J, Honig A. Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res. 2010;30(5):1653-1659.
152. Diaz-Moralli S, Tarrado-Castellarnau M, Alenda C, Castells A, Cascante M. Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation. PLoS One. 2011;6(9):e25323.
153. Feyen O, Coy JF, Prasad V, Schierl R, Saenger J, Baum RP. EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-1359.
154. Fritz P, Coy JF, Mürdter TE, Ott G, Alscher MD, Friedel G. TKTL-1 expression in lung cancer. Pathol Res Pract. 2012;208(4):203-209.
155. Comin-Anduix B, Boren J, Martinez S, Moro C, Centelles JJ, Trebukhina R, Petushok N, Lee WN, Boros LG, Cascante M. The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. Eur J Biochem. 2001;268(15):4177-4182.
156. Yang CM, Liu YZ, Liao JW, Hu ML. The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action. Clin Exp Metastasis. 2010;27(5):341-349.
157. Thomas AA, Le Huerou Y, De Meese J, Gunawardana I, Kaplan T, Romoff TT, Gonzales SS, Condroski K, Boyd SA, Ballard J, Bernat B, DeWolf W, Han M, et al. Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors. Bioorg Med Chem Lett. 2008;18(6):2206-2210.
158. Langbein S, Frederiks WM, zur Hausen A, Popa J, Lehmann J, Weiss C, Alken P, Coy JF. Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer. 2008;122(11):2422-2428.
159. Mayer A, von Wallbrunn A, Vaupel P. Glucose metabolism of malignant cells is not regulated by transketolase-like (TKTL)-1. Int J Oncol. 2010;37(2):265-271.
160. Maslova AO, Meshalkina LE, Kochetov GA. Computer modeling of transketolase-like protein, TKTL1, a marker of certain tumor tissues. Biochemistry (Mosc). 2012;77(3):296-299.
161. Jones NP, Schulze A. Targeting cancer metabolism-aiming at a tumour's sweet-spot. Drug Discov Today. 2012;17(5-6):232-241.
162. Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Resipr J. 1996;9(8):1736-1742.
163. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 1997;94(13):6658-6663.
164. Zhuang L, Scolyer RA, Murali R, McCarthy SW, Zhang XD, Thompson JF, Hersey P. Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Mod Pathol. 2010;23(1):45-53.
165. Koukourakis MI, Giatromanolaki A, Winter S, Leek R, Sivridis E, Harris A. Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or postoperative radiotherapy. Oncology. 2009;77(5):285-292.
166. Dhup S, Dadhich RK, Porporato PE, Sonveaux P. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des. 2012;18(10):1319-1330.
167. Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F. Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol. 2010;2010:427694.
168. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Bröer S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J. 2000;350(Pt 1):219-227.
169. Gerlinger M, Santos CR, Spencer-Dene B, Martinez P, Endesfelder D, Burrell RA, Vetter M, Jiang M, Saunders RE, Kelly G, Dykema K, Rioux-Leclercq N, Stamp G, et al. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol. 2012;227(2):146-156.
170. Fisel P, Kruck S, Winter S, Bedke J, Hennenlotter J, Nies AT, Scharpf M, Fend F, Stenzl A, Schwab M, Schaeffeler E. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome. Clin Cancer Res. 2013;19(18):5170-5181.
171. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177-185.
172. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra. Energy metabolism in tumor cells. FEBS J. 2007;274(6):1393-1418.
173. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325-337.
174. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11-20.
175. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005;8(4):311-321.
176. Zaidi N, Swinnen JV, Smans K. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res. 2012;72(15):3709-3714.
177. Schwartz L, Abolhassani M, Guais A, Sanders E, Steyaert JM, Campion F, Israel M. A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results. Oncol Rep. 2010;23(5):1407-1416.
178. Abramson HN. The lipogenesis pathway as a cancer target. J Med Chem. 2011;54(16):5615-5638.
179. Horiguchi A, Asano T Asano T, Ito K, Sumitomo M, Hayakawa M. Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J Urol. 2008;180(3):1137-1140.
180. Hakimi AA, Furberg H, Zabor EC, Jacobsen A, Schultz N, Ciriello G, Mikklineni N, Fiegoli B, Kim PH, Voss MH, Shen H, Laird PW, Sander C, et al. An epidemiological and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst. 2013;105(24):1862-1870.
181. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009;324(5930):1076-1080.
182. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Matés JM, DeBerardinis RJ. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci USA. 2011;108(21):8674-8679.
183. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2012;2(10):881-898.
184. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29(3):313-324.
185. Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol. 2012;23(4):362-369.
186. Ruiz-Perez MV, Sanchez-Jiminez F, Alonso FJ, Segura JA, Marquez J, Medina MA. Glutamine, glucose and other fuels for cancer. Curr Pharm Des. 2014;20(15):2557-2579.
187. Mates JM, Segura JA, Martin-Rufian M, Campos-Sandoval JA, Alonso FJ, Marquez J. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med. 2013;13(4):514-534.
188. van den Heuvel AP, Jing J, Wooster RF, Bachman KE. Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variety GAC is essential for cancer cell growth. Cancer Biol Ther. 2012;13(12):1185-1194.
189. Pajic T, Cernelc P, Sesek Briski A, Lejko-Zupanc T, Malesic I. Glutamate dehydrogenase activity in lymphocytes of B-cell chronic lymphocytic leukaemia patients. Clin Biochem. 2009;42(16-17):1677-1684.
190. McGivan JD, Bungard CI. The transport of glutamine into mammalian cells. Front Biosci. 2007;12:874-882.
191. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15(4):254-266.
192. Fuchs BC, Finger RE, Onan MC, Bode BP. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol. 2007;293(1):C55-63.
193. Erickson JW, Cerione RA. Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget. 2010;1(8):734-740.
194. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA. 2008;105(48):18782-18787.
195. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762-765.
196. Stumvoll M, Perriello G, Meyer C, Gerich J. Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Kidney Int. 1999;55(3):778-792.
197. Curi R, Newsholme P, Procopio J, Lagranha C, Gorjao R, Pithon-Curi TC. Glutamine, gene expression, and cell function. Front Biosci. 2007;12:344-357.
198. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123(9):3678-3684.
199. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, Kelleher JK, Vander Heiden MG, Iliopoulos O, Stephanopoulos G. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2011;481(7381):380-384.
200. Gameiro PA, Yang J, Metelo AM, Perez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, Lopez-Larrubia P, Stephanopoulos G, Iliopoulos O. In vivo HIFmediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 2013;17(3):372-385.
201. Filipp FV, Scott DA, Ronal ZA, Osterman AL, Smith JW. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res. 2012;25(3):375-383.
202. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG, Simon MC, Thompson CB. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of a-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA. 2011;108(49):19611-19616.
203. Moreno-Sanchez R, Marin-Hernandez A, Saavedra E, Pardo JP, Ralph SJ, Rodriguez-Enriquez S. Who controls the ATP supply in cancer cells? Biochemistry lessons to understand cancer energy metabolism. Int J Biochem Cell Biol. 2014;50:10-23.
204. Iacobazzi V, Palmieri F, Runswick MJ, Walker JE. Sequences of the human and bovine genes for the mitochondrial 2-oxoglutarate carrier. DNA Seq. 1992;3(2):79-88.
205. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, et al. Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway. Nature. 2013;496(7443):101-105.
206. Lyssiotis CA, Son J, Cantley LC, Kimmelman AC. Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance. Cell Cycle. 2013;12(13):1987-1988.
207. Matsuno T. Pathway of glutamate oxidation and its regulation in the HuH13 line of human hepatoma cells. J Cell Physiol. 1991;148(2):290-294.
208. Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, Alberghina L, Stephanopoulos G, Chiaradonna F. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011;7:523.
209. White NM, Masui O, Desouza LV, Krakovska O, Metias S, Romaschin AD, Honey RJ, Stewart R, Pace K, Lee J, Jewett MA, Bjarnason GA, Siu KW, Yousef G. Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma. Oncotarget. 2014;5(2):506-518.
210. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104(49):19345-19350.
211. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamine dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009;69(20):7986-7993.
212. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, Zimmerman LJ, Liebler DC, Slebos RJ, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B-cells. Cell Metab. 2012;15(1):110-121.
213. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, Myer VE, MacKeigan JP, Porter JA, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136(3):521-534.
214. Hassanein M, Hoeksema MD, Shiota M, Qian J, Harris BK, Chen H, Clark JE, Alborn WE, Eisenberg R, Massion PP. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res. 2013;19(3):560-570.
215. Wang Q, Beaumont KA, Otte NJ, Font J, Bailey CG, van Geldermalsen M, Sharp DM, Tiffen JC, Ryan RM, Jormakka M, Haass NK, Rasko JE, Holst J. Targeting glutamine transport to suppress melanoma cell growth. Int J Cancer. 2014;135(5):1060-1071.
216. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandev A, Semenza GL. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011;145(5):732-744.
217. Chaneton B, Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem Sci. 2012;37(8):309-316.
218. Jewett MA, Zuniga A. Renal tumor natural history: the rational and role for active surveillance. Urol Clin North Am. 2008;35(4):627-634.
219. Organ M, Jewett M, Basiuk J, Morash C, Pautler S, Siemens DR, Tanguay S, Gleave M, Drachenberg D, Chow R, Chin J, Evans A, Fleshner N, et al. Growth kinetics of small renal masses: a prospective analysis from the Renal Cell Carcinoma Consortium of Canada. Can Urol Assoc J. 2014;8(1-2):24-27.
220. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res. 2006;66(10): 5216-5223.
221. Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahi ML, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 2008;118(12):3930-3942.
222. Fischer S, Schlosser E, Mueller M, Csaba N, Merkle HP, Groettrup M, Gander. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Target. 2009;17(8):652-661.
223. Choi SY, Collins CC, Gout PW, Wang Y. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol. 2013;230(4):350-355.
224. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, Cline GW, Phillips AJ, Medzhitov R. Functional polarization of tumour-associated macrophages by tumourderived lactic acid. Nature. 2014;513(7519):559-563.
225. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011;71(22):6921-6925.
226. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer. 2003;3:31.
227. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43-49.
228. Hernandez Patino CE, Jaime-Munoz G, Resendis-Antonio O. Systems biology of cancer: moving toward the integrative study of the metabolic alterations in cancer cells. Front Physiol. 2013,;3:481.
229. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christmas R, Avila-Campilo I, Creech M, Gross B, Hanspers K, Isserlin R, Kelley R, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007;2(10):2366-2382.
230. Kelder T, Pico AR, Hanspers K, van Iersel MP, Evelo C, Conklin BR. Mining biological pathways using WikiPathways web services. PLoS One. 2009;4(7):e6447.